Aker BioMarine Valuation
Is AKBM undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of AKBM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: AKBM (NOK101.4) is trading below our estimate of fair value (NOK172.09)
Significantly Below Fair Value: AKBM is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AKBM?
Other financial metrics that can be useful for relative valuation.
What is AKBM's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$829.45m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 2.9x |
Enterprise Value/EBITDA | 17.9x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does AKBM's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 1.1x | ||
GSF Grieg Seafood | 0.9x | 12.1% | NOK 6.0b |
AUSS Austevoll Seafood | 0.5x | 6.1% | NOK 18.7b |
ISLAX Icelandic Salmon | 2.2x | 20.3% | NOK 3.3b |
LSG Lerøy Seafood Group | 0.9x | 5.5% | NOK 28.8b |
AKBM Aker BioMarine | 2.5x | 3.4% | NOK 8.9b |
Price-To-Sales vs Peers: AKBM is expensive based on its Price-To-Sales Ratio (2.5x) compared to the peer average (1.1x).
Price to Earnings Ratio vs Industry
How does AKBM's PE Ratio compare vs other companies in the NO Food Industry?
Price-To-Sales vs Industry: AKBM is expensive based on its Price-To-Sales Ratio (2.5x) compared to the Norwegian Food industry average (2.2x).
Price to Sales Ratio vs Fair Ratio
What is AKBM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 2.5x |
Fair PS Ratio | 0.6x |
Price-To-Sales vs Fair Ratio: AKBM is expensive based on its Price-To-Sales Ratio (2.5x) compared to the estimated Fair Price-To-Sales Ratio (0.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | NOK 101.40 | NOK 107.68 +6.2% | 11.8% | NOK 120.34 | NOK 95.02 | n/a | 2 |
Sep ’25 | NOK 104.00 | NOK 106.98 +2.9% | 12.1% | NOK 119.94 | NOK 94.02 | n/a | 2 |
Aug ’25 | NOK 95.90 | NOK 93.79 -2.2% | 4.1% | NOK 97.66 | NOK 89.92 | n/a | 2 |
Jul ’25 | NOK 85.40 | NOK 79.07 -7.4% | 14.0% | NOK 90.17 | NOK 67.97 | n/a | 2 |
Jun ’25 | NOK 78.50 | NOK 75.83 -3.4% | 11.9% | NOK 84.85 | NOK 66.82 | n/a | 2 |
May ’25 | NOK 70.20 | NOK 73.08 +4.1% | 3.2% | NOK 75.43 | NOK 70.72 | n/a | 2 |
Apr ’25 | NOK 64.00 | NOK 55.44 -13.4% | 8.3% | NOK 60.01 | NOK 50.86 | n/a | 2 |
Mar ’25 | NOK 54.00 | NOK 54.85 +1.6% | 9.3% | NOK 59.95 | NOK 49.76 | n/a | 2 |
Feb ’25 | NOK 45.00 | NOK 43.49 -3.4% | 3.6% | NOK 45.06 | NOK 41.93 | n/a | 2 |
Jan ’25 | NOK 46.00 | NOK 42.98 -6.6% | 4.9% | NOK 45.09 | NOK 40.88 | n/a | 2 |
Dec ’24 | NOK 40.75 | NOK 43.97 +7.9% | 2.4% | NOK 45.00 | NOK 42.93 | n/a | 2 |
Nov ’24 | NOK 39.25 | NOK 44.95 +14.5% | 0.2% | NOK 45.06 | NOK 44.84 | n/a | 2 |
Oct ’24 | NOK 39.30 | NOK 45.07 +14.7% | 0.1% | NOK 45.13 | NOK 45.01 | n/a | 2 |
Sep ’24 | NOK 45.55 | NOK 45.07 -1.1% | 0.1% | NOK 45.13 | NOK 45.01 | NOK 104.00 | 2 |
Aug ’24 | NOK 41.85 | NOK 45.07 +7.7% | 0.1% | NOK 45.13 | NOK 45.01 | NOK 95.90 | 2 |
Jul ’24 | NOK 34.05 | NOK 47.44 +39.3% | 5.5% | NOK 50.04 | NOK 44.83 | NOK 85.40 | 2 |
Jun ’24 | NOK 35.30 | NOK 47.36 +34.2% | 5.0% | NOK 49.75 | NOK 44.97 | NOK 78.50 | 2 |
May ’24 | NOK 39.95 | NOK 44.90 +12.4% | 15.3% | NOK 51.79 | NOK 38.02 | NOK 70.20 | 2 |
Apr ’24 | NOK 38.85 | NOK 43.50 +12.0% | 17.1% | NOK 50.95 | NOK 36.04 | NOK 64.00 | 2 |
Mar ’24 | NOK 38.80 | NOK 42.99 +10.8% | 16.3% | NOK 50.01 | NOK 35.98 | NOK 54.00 | 2 |
Feb ’24 | NOK 36.00 | NOK 45.22 +25.6% | 16.0% | NOK 52.44 | NOK 38.00 | NOK 45.00 | 2 |
Jan ’24 | NOK 38.05 | NOK 47.86 +25.8% | 15.8% | NOK 55.44 | NOK 40.28 | NOK 46.00 | 2 |
Dec ’23 | NOK 37.30 | NOK 47.86 +28.3% | 15.8% | NOK 55.44 | NOK 40.28 | NOK 40.75 | 2 |
Nov ’23 | NOK 38.30 | NOK 52.92 +38.2% | 12.6% | NOK 59.90 | NOK 43.94 | NOK 39.25 | 3 |
Oct ’23 | NOK 44.85 | NOK 60.45 +34.8% | 8.8% | NOK 66.69 | NOK 53.75 | NOK 39.30 | 3 |
Sep ’23 | NOK 51.90 | NOK 57.95 +11.7% | 12.1% | NOK 66.38 | NOK 48.95 | NOK 45.55 | 4 |
Analyst Forecast: Target price is less than 20% higher than the current share price.